Pentasystem embolism associated with transient antiphospholipid antibodies in severe M. pneumoniae pneumonia: a "Dual-Hit" case report and systematic review.
Hu Y, Chen J, et al. • Frontiers in immunology • 2026
This study is consistent with the 'dual-hit' model in SMPP, where systemic inflammation may prime the endothelium and transient aPL positivity coincides with an extensive thrombotic burden, supporting low-threshold vascular imaging and aPL screening in pediatric severe Mycoplasma pneumoniae pneumonia.
Key Findings
Results
A 6-year-old boy with severe Mycoplasma pneumoniae pneumonia (SMPP) developed extensive multi-system thrombosis coinciding with hyperinflammation and transient antiphospholipid antibodies (aPLs) that seroconverted to negative upon recovery.
The index case involved pentasystem (five-system) embolism associated with transient aPLs in the setting of SMPP.
Thrombosis coincided temporally with hyperinflammation and aPL positivity.
aPLs seroconverted to negative upon clinical recovery, consistent with a transient rather than persistent autoimmune phenomenon.
The case illustrates the 'dual-hit' hypothesis involving both infection-induced inflammation and transient aPLs.
Results
A systematic review of 19 studies comprising 199 pediatric SMPP cases found multi-system thrombotic involvement in 27.1% of cases.
The systematic review covered literature published from January 2020 to December 2025.
19 studies were identified in the pooled analysis.
54 out of 199 cases (27.1%) demonstrated multi-system involvement.
The high prevalence of multi-system involvement supports a low threshold for vascular imaging in pediatric SMPP.
Results
Among pediatric SMPP patients tested for antiphospholipid antibodies, aPL positivity was found in 69.2% of cases.
aPL testing was performed in 65 patients, representing 32.7% of the total cohort of 199 cases.
45 out of 65 tested patients were aPL positive (69.2%).
The high rate of aPL positivity suggests that testing was likely selectively performed in more severe or thrombotic cases, potentially inflating the observed prevalence.
aPLs were characterized as transient and interpreted as a potential risk-amplifying biomarker rather than a proven causal driver of thrombosis.
Results
Most pediatric SMPP patients with thrombosis achieved favorable outcomes with anticoagulation and immunomodulation.
Favorable outcomes were observed across the pooled cohort of 199 cases.
Treatment approaches included anticoagulation therapy and immunomodulation.
The paper supports biomarker-guided management strategies for these patients.
The authors advocate for aPL screening as part of management given the high prevalence of positivity among tested patients.
Discussion
The findings are consistent with a 'dual-hit' model in which systemic inflammation primes the endothelium and transient aPL positivity amplifies thrombotic risk in SMPP.
The 'dual-hit' hypothesis posits synergy between infection-induced inflammation and transient antiphospholipid antibodies.
The authors state that 'systemic inflammation may prime the endothelium and transient aPL positivity coincides with an extensive thrombotic burden.'
Transient aPLs are described as 'a potential risk-amplifying biomarker rather than a proven causal driver of thrombosis.'
The authors note that the immunothrombotic mechanisms of thromboembolism in SMPP 'remain poorly defined,' and this study provides integrated clinical support for the dual-hit model without establishing causation.
Conclusions
The authors recommend low-threshold vascular imaging and aPL screening in pediatric SMPP, along with biomarker-guided management.
The high prevalence of multi-system involvement (27.1%) is cited as justification for routine or low-threshold vascular imaging.
The high aPL positivity rate (69.2% among tested patients) supports aPL screening as a clinical practice.
Biomarker-guided management is advocated based on the findings.
The clinical spectrum and immunothrombotic mechanisms of thromboembolism in SMPP were noted to be 'poorly defined' prior to this study.
What This Means
This research examines a rare but serious complication of severe Mycoplasma pneumoniae pneumonia (a type of 'walking pneumonia') in children: the development of blood clots in multiple organ systems simultaneously. The paper combines a detailed report of a 6-year-old boy who developed clots in five different body systems with a systematic review of 199 similar pediatric cases reported in the medical literature between 2020 and 2025. Key findings include that over one in four patients (27.1%) had clots affecting multiple organ systems, and among those tested for a type of immune protein called antiphospholipid antibodies (aPLs), nearly 70% tested positive — though these antibodies were transient, disappearing as patients recovered.
The study provides clinical support for a 'dual-hit' theory of how these clots form: the severe infection triggers widespread inflammation that makes blood vessel walls more vulnerable, while simultaneously causing the immune system to temporarily produce antibodies that further promote clotting. Importantly, these antibodies appear to be a marker associated with increased clotting risk during the illness rather than a confirmed direct cause. Most patients in the review recovered well when treated with blood thinners and immune-modulating therapies.
This research suggests that doctors caring for children with severe Mycoplasma pneumoniae pneumonia should have a low threshold for checking for blood clots in multiple body systems using imaging, and should consider testing for antiphospholipid antibodies. The presence of these transient antibodies may help identify children at higher risk for extensive clotting who might benefit from more aggressive monitoring and treatment. However, the authors caution that the antibodies should be viewed as a risk marker rather than definitive proof of an underlying autoimmune condition, since they disappear after recovery.
Hu Y, Chen J, Wu L, Xu J, Xu X, Du J, et al.. (2026). Pentasystem embolism associated with transient antiphospholipid antibodies in severe M. pneumoniae pneumonia: a "Dual-Hit" case report and systematic review.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1845246